<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700464</url>
  </required_header>
  <id_info>
    <org_study_id>UC-EpiCheck-FDA-01</org_study_id>
    <nct_id>NCT02700464</nct_id>
  </id_info>
  <brief_title>The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma</brief_title>
  <official_title>The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nucleix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder&#xD;
      EpiCheck test compared to the gold standard cystoscopy and pathology in patients under&#xD;
      monitoring for recurrence of bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA&#xD;
      methylation patterns in urine that are associated with bladder cancer. It is intended for use&#xD;
      as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy&#xD;
      inpatients previously diagnosed with bladder cancer This is a, multicenter, prospective,&#xD;
      blinded study to evaluate the efficacy (sensitivity and specificity) of a novel methylation&#xD;
      test for the detection of recurrent Urothelial Cell Carcinoma in patients with a history of&#xD;
      bladder cancer undergoing surveillance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specificity of Bladder EpiCheck Urine Test Kit (the proportion of negatives that are correctly identified as such by the gold standard)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of Bladder EpiCheck Urine Test Kit (The proportion of positives that are correctly identified as such by the gold standard)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">680</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Bladder EpiCheck Urine Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bladder EpiCheck Urine Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cystoscopy and pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bladder EpiCheck Urine Test</intervention_name>
    <description>The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer</description>
    <arm_group_label>Bladder EpiCheck Urine Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cystoscopy and pathology</intervention_name>
    <description>Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy</description>
    <arm_group_label>Gold Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any male or female patient diagnosed with incident or recurrent Urothelial Cell&#xD;
             Carcinoma and undergoing surveillance at 3 month intervals.&#xD;
&#xD;
          -  Has had all urothelial cell carcinoma tumor resected within the past 12 months&#xD;
&#xD;
          -  Has a plan for cystoscopic surveillance (adjuvant intravesical therapy allowed)&#xD;
&#xD;
          -  Able to provide legally effective informed consent&#xD;
&#xD;
          -  Able to produce 45mL of urine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell&#xD;
             Carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shmulik Adler, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Nucleix Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology, P.C.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Urology</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Surgeons of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN, Princess Margret Cancer center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

